Neuronetics (NASDAQ:STIM) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPS

Neuronetics (NASDAQ:STIM) posted its earnings results on Tuesday. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08), Zacks reports. Neuronetics had a negative net margin of 50.09% and a negative return on equity of 141.24%. The company had revenue of $31.98 million during the quarter, compared to the consensus estimate of $29.07 million. Neuronetics updated its Q2 2025 guidance to EPS and its FY 2025 guidance to EPS.

Neuronetics Price Performance

Neuronetics stock opened at $4.50 on Wednesday. Neuronetics has a 52 week low of $0.52 and a 52 week high of $5.92. The company’s 50 day moving average price is $4.25 and its two-hundred day moving average price is $2.76. The stock has a market cap of $296.17 million, a P/E ratio of -3.66 and a beta of 1.92. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90.

Insider Activity

In other Neuronetics news, CFO Stephen Furlong sold 17,307 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $4.11, for a total value of $71,131.77. Following the completion of the transaction, the chief financial officer now owns 454,420 shares in the company, valued at $1,867,666.20. This represents a 3.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Keith J. Sullivan sold 40,992 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $3.28, for a total value of $134,453.76. Following the sale, the chief executive officer now directly owns 1,283,362 shares of the company’s stock, valued at approximately $4,209,427.36. This represents a 3.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 100,369 shares of company stock valued at $358,929 over the last three months. Corporate insiders own 8.70% of the company’s stock.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group lifted their price objective on shares of Neuronetics from $5.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.